Literature DB >> 25330801

A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer.

Martha L Slattery1, Roger K Wolff2, Abbie Lundgreen2.   

Abstract

Inflammation, hormones and energy-related factors have been associated with colorectal cancer (CRC) and it has been proposed that convergence and interactions of these factors importantly influence CRC risk. We have previously hypothesized that genetic variation in the CHIEF (convergence of hormones, inflammation and energy-related factors) pathway would influence risk of CRC. In this paper, we utilize an Adaptive Rank Truncation Product (ARTP) statistical method to determine the overall pathway significance and then use that method to identify the key elements within the pathway associated with disease risk. Data from two population-based case-control studies of colon (n = 1555 cases and 1956 controls) and rectal (n = 754 cases and 959 controls) cancer were used. We use ARTP to estimate pathway and gene significance and polygenic scores based on ARTP findings to further estimate the risk associated with the pathway. Associations were further assessed based on tumor molecular phenotype. The CHIEF pathway was statistically significant for colon cancer (P(ARTP)= 0.03) with the most significant interferons (P(ARTP) = 0.0253), JAK/STAT/SOCS (P(ARTP) = 0.0111), telomere (P(ARTP) = 0.0399) and transforming growth factor β (P(ARTP) = 0.0043) being the most significant subpathways for colon cancer. For rectal cancer, interleukins (P(ARTP) = 0.0235) and selenoproteins (P ARTP = 0.0047) were statistically significant although the pathway overall was of borderline significance (P(ARTP) = 0.06). Interleukins (P(ARTP) = 0.0456) and mitogen-activated protein kinase (P(ARTP) = 0.0392) subpathways were uniquely significant for CpG island methylator phenotype-positive colon tumors. Increasing number of at-risk alleles was significantly associated with both colon [odds ratio (OR) = 6.21, 95% confidence interval (CI): 4.72, 8.16] and rectal (OR = 7.82, 95% CI: 5.26, 11.62) cancer. We conclude that elements of the CHIEF pathway are important for CRC risk.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25330801      PMCID: PMC4291046          DOI: 10.1093/carcin/bgu213

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  51 in total

Review 1.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

2.  Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Roger K Wolff; Jennifer S Herrick; Bette J Caan
Journal:  Dis Colon Rectum       Date:  2012-05       Impact factor: 4.585

Review 3.  Cross-talk between nuclear receptors and nuclear factor kappaB.

Authors:  K De Bosscher; W Vanden Berghe; G Haegeman
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

4.  A comparison of colon and rectal somatic DNA alterations.

Authors:  Martha L Slattery; Karen Curtin; Roger K Wolff; Kenneth M Boucher; Carol Sweeney; Sandra Edwards; Bette J Caan; Wade Samowitz
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

5.  PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States).

Authors:  Martha L Slattery; Karen Curtin; Roger Wolff; Khe Ni Ma; Carol Sweeney; Maureen Murtaugh; John D Potter; Theodore R Levin; Wade Samowitz
Journal:  Cancer Causes Control       Date:  2006-04       Impact factor: 2.506

Review 6.  Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

Authors:  D Grahame Hardie
Journal:  Endocrinology       Date:  2003-09-04       Impact factor: 4.736

Review 7.  Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models.

Authors:  B Viollet; F Andreelli; S B Jørgensen; C Perrin; D Flamez; J Mu; J F P Wojtaszewski; F C Schuit; M Birnbaum; E Richter; R Burcelin; S Vaulont
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

8.  Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk.

Authors:  Ulrike Peters; Richard B Hayes; Nilanjan Chatterjee; Wen Shao; Robert E Schoen; Paul Pinsky; Bruce W Hollis; Katherine A McGlynn
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-04       Impact factor: 4.254

9.  Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway.

Authors:  Suntaek Hong; Chan Lee; Seong-Jin Kim
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 10.  Role of transforming growth factor-beta superfamily signaling pathways in human disease.

Authors:  Kelly J Gordon; Gerard C Blobe
Journal:  Biochim Biophys Acta       Date:  2008-02-11
View more
  8 in total

1.  Gene-diet interactions and their impact on colorectal cancer risk.

Authors:  Elizabeth D Kantor; Edward L Giovannucci
Journal:  Curr Nutr Rep       Date:  2015-03

2.  Genes, environment and gene expression in colon tissue: a pathway approach to determining functionality.

Authors:  Martha L Slattery; Daniel F Pellatt; Roger K Wolff; Abbie Lundgreen
Journal:  Int J Mol Epidemiol Genet       Date:  2016-03-23

3.  The influence of the CHIEF pathway on colorectal cancer-specific mortality.

Authors:  Martha L Slattery; Abbie Lundgreen
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

4.  Genetic variants in the TGFβ-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.

Authors:  Martha L Slattery; Andromahi Trivellas; Andrew J Pellatt; Lila E Mullany; John R Stevens; Roger K Wolff; Jennifer S Herrick
Journal:  Oncotarget       Date:  2017-03-07

5.  The TGFβ-signaling pathway and colorectal cancer: associations between dysregulated genes and miRNAs.

Authors:  Andrew J Pellatt; Lila E Mullany; Jennifer S Herrick; Lori C Sakoda; Roger K Wolff; Wade S Samowitz; Martha L Slattery
Journal:  J Transl Med       Date:  2018-07-09       Impact factor: 5.531

6.  Identifying factors associated with the direction and significance of microRNA tumor-normal expression differences in colorectal cancer.

Authors:  John R Stevens; Jennifer S Herrick; Roger K Wolff; Martha L Slattery
Journal:  BMC Cancer       Date:  2017-10-30       Impact factor: 4.430

7.  Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.

Authors:  Xiao-Bo Ma; Yuan-Yuan Xu; Meng-Xuan Zhu; Lu Wang
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

Review 8.  MicroRNA-Assisted Hormone Cell Signaling in Colorectal Cancer Resistance.

Authors:  Crescenzo Massaro; Elham Safadeh; Giulia Sgueglia; Hendrik G Stunnenberg; Lucia Altucci; Carmela Dell'Aversana
Journal:  Cells       Date:  2020-12-30       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.